Literature DB >> 28398332

Drugmakers accused of exploiting orphan drug incentives, fueling price problem.

Brady Huggett1.   

Abstract

Year:  2017        PMID: 28398332     DOI: 10.1038/nbt0417-301

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  America's drug problem.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2016-11-14       Impact factor: 54.908

2.  Spinal muscular atrophy approval boosts antisense drugs.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-02-08       Impact factor: 54.908

3.  Sovaldi makes blockbuster history, ignites drug pricing unrest.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908

4.  Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance.

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2016-07-12       Impact factor: 54.908

  4 in total
  1 in total

1.  US tax reform may jeopardize orphans.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2018-02-06       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.